143 related articles for article (PubMed ID: 37311441)
1. EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target.
Lin Z; Tang L; Chen S; Zhang W; Lin J; Gao H; Zhang P
Ophthalmic Res; 2023; 66(1):1014-1019. PubMed ID: 37311441
[TBL] [Abstract][Full Text] [Related]
2. The role of EZH2 as a potential therapeutic target in retinoblastoma.
Zhao Y; Cheng Y; Qu Y
Exp Eye Res; 2023 Feb; 227():109389. PubMed ID: 36669714
[TBL] [Abstract][Full Text] [Related]
3. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.
Khan M; Walters LL; Li Q; Thomas DG; Miller JM; Zhang Q; Sciallis AP; Liu Y; Dlouhy BJ; Fort PE; Archer SM; Demirci H; Dou Y; Rao RC
Lab Invest; 2015 Nov; 95(11):1278-90. PubMed ID: 26280220
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
5. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
8. The PRC2 complex directly regulates the cell cycle and controls proliferation in skeletal muscle.
Adhikari A; Davie JK
Cell Cycle; 2020 Sep; 19(18):2373-2394. PubMed ID: 32816597
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
11. MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2.
Lei Q; Shen F; Wu J; Zhang W; Wang J; Zhang L
Oncol Rep; 2014 Jul; 32(1):261-9. PubMed ID: 24807198
[TBL] [Abstract][Full Text] [Related]
12. EZH2 is highly expressed in pituitary adenomas and associated with proliferation.
Schult D; Hölsken A; Siegel S; Buchfelder M; Fahlbusch R; Kreitschmann-Andermahr I; Buslei R
Sci Rep; 2015 Nov; 5():16965. PubMed ID: 26593398
[TBL] [Abstract][Full Text] [Related]
13. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
[TBL] [Abstract][Full Text] [Related]
14. EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
Liu B; Pang B; Wang Q; Yang S; Gao T; Ding Q; Liu H; Yang Y; Fan H; Zhang R; Xin T; Xu G; Pang Q
Hum Pathol; 2017 Aug; 66():101-107. PubMed ID: 28666925
[TBL] [Abstract][Full Text] [Related]
15. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.
Coe BP; Thu KL; Aviel-Ronen S; Vucic EA; Gazdar AF; Lam S; Tsao MS; Lam WL
PLoS One; 2013; 8(8):e71670. PubMed ID: 23967231
[TBL] [Abstract][Full Text] [Related]
16. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
[TBL] [Abstract][Full Text] [Related]
17. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
18. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA
Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
20. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
